TRANSFORMING MILITARY MEDICINE TO SAVE LIVES WORLDWIDE

It is a privilege to continue leading The Geneva Foundation, especially as we enter our 30th year in service of our mission to advance military medicine through research, development, and education. I’m proud of our history and equally excited for the future – building upon Geneva’s strong foundation to expand our global impact and accelerate military medicine for all.

#TeamGeneva takes pride and purpose in playing a key role in optimizing the health of service members and the communities in which they serve.

As a global organization with over 50 locations and 413 employees, Geneva continues to grow in pursuit of our vision to lead the way in transforming military medicine to save lives worldwide. This year, Geneva deepened its roots in San Antonio with the designation of the Autonomous Reanimation and Evacuation (AREVA) research program to improve care for critically injured service members in combat. Geneva’s Fort Bragg Research Institute, now renamed the Fort Liberty Research Institute (FLRI), expanded its footprint to continue to deliver human performance research solutions to the Department of Defense (DoD).

In 2022, Geneva enhanced its executive leadership with the addition of Matt Rueckert, MA, MBA, as Chief Operating Officer. The organization also welcomed MG (Ret) Barb Holcomb, RN and Jonathan Miller, PhD, JD, to the Board of Directors and LTC (Ret) Ann Ketz, PhD, and COL (Ret) Steve Svoboda, MD, to the Scientific Advisory Board. The additions of these critical, strategic leaders will continue to enhance Geneva’s scientific impact and strategic direction.

Geneva’s Scientific Advisory Board was proud to honor LTC (Ret) Christopher Colombo, MD, as Researcher of the Year in recognition of his impactful solutions for emerging threats and emergency response efforts. Dr. Colombo led the development of a comprehensive and flexible National Emergency Tele-Critical Care Network (NETCCN) framework to provide urgently needed assistance during the COVID-19 pandemic to 35+ hospitals nationwide.

Geneva’s collaboration with Uniformed Services University (USU) continues to mature, as seen in the USU-4D Bio³ Center for Biotechnology (4DBio³) and the Musculoskeletal Injury Rehabilitation Research for Operational Readiness (MIRROR) program. In 2022, 4DBio³ received an additional $12M in federal funding to produce on-demand blood products for service members. MIRROR researchers at Madigan Army Medical Center are developing a biorepository that could be the most comprehensive musculoskeletal biobank within the DoD. The TriService Nursing Research Program (TSNRP) celebrated 30 years of funding military nursing research and evidence-based practice. Geneva’s history with TSNRP dates to 1996, when we received our first federally funded research grant from TSNRP. Today, we’re proud to serve in a program management role to administer the activities.

Geneva continued to expand research solutions through chemical, biological, radiological, nuclear, and explosives (CBNRE) defense-based acquisition lifecycle research. The U.S. Army awarded Geneva and ERP International the U.S. Army Combat Capabilities Development Command, Chemical Biological Center (DEVCOM CBC) Scientific, Technical, Engineering, and Program Support Services (STEPSS) contract to develop CBRNE solutions for the warfighter. Geneva is eager to continue driving impactful research outcomes through this critical contract vehicle.

We are immensely grateful for your steadfastness to Geneva’s mission. With your continued support, we are confident in our ability to build upon our achievements in 2022 and equally successful next three decades. As we look ahead, we are filled with hope and optimism for the future of military medical research. We are honored to play a crucial role in ensuring the best health outcomes for all.

Sincerely, Elise W. Huszar, MBA
President & CEO